BlackRock, Inc. vs Johnson & Johnson: Strategic Comparison

This in-depth comparison examines BlackRock, Inc. and Johnson & Johnson across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching BlackRock, Inc. on its own, evaluating Johnson & Johnson, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between BlackRock, Inc. and Johnson & Johnson is widest.

On the headline numbers, BlackRock, Inc. reports annual revenue of $24.2B against $94.2B for Johnson & Johnson, while their respective market capitalizations stand at $166.2B and $643.9B. Both BlackRock, Inc. and Johnson & Johnson are headquartered in United States, so they compete in a shared home market and regulatory environment.

BlackRock, Inc.: BlackRock is a New York-based investment manager listed on the NYSE as BLK and included in the S&P 500. It managed $15.3 trillion at June 30, 2026, more than any other firm, for pension funds, insurers, sovereign wealth funds, financial advisors and individuals in more than 100 countries. Larry Fink has been Chairman and CEO since founding it in 1988, and co-founder Rob Kapito is President. About 60% of its roughly 24,900 employees work outside the United States. Because its index funds hold sizable stakes in most large public companies, BlackRock's proxy votes and public statements are closely watched.

Johnson & Johnson: Johnson & Johnson is one of the largest healthcare companies in the world by revenue and market value. Once known for Band-Aid, Tylenol, and baby powder, it moved those consumer brands into Kenvue in 2023 and now reports two segments: Innovative Medicine and MedTech. In 2025 it generated $94.2 billion in sales with about 140,800 employees, and in 2026 it is aiming for more than $100 billion in revenue during its 140th year.

BlackRock, Inc. and Johnson & Johnson pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between BlackRock, Inc. and Johnson & Johnson.

BlackRock, Inc. business model: BlackRock makes money in three main ways. The largest is base management and administration fees, charged as a percentage of the assets it runs across iShares ETFs, index and active funds, cash funds and institutional mandates. The second is technology services and subscription revenue from Aladdin, eFront and Preqin, which reached about $2.0 billion in 2025, up 24%. The third is performance fees and securities lending revenue, which swing with markets and fund results; performance fees rose to $305 million in Q2 2026 after HPS's private credit funds were added. Core iShares funds charge as little as 0.03% a year, so the index business depends on enormous scale, while private markets and technology earn far more per dollar. Management wants those two areas to supply more than 30% of revenue by 2030.

Johnson & Johnson business model: J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal. Margins depend on patent protection, so growth relies on launching new drugs as older ones such as STELARA face biosimilars. MedTech (about 36%, $33.8 billion) sells surgical tools, wound closure, orthopaedic implants, electrophysiology catheters and mapping systems, Abiomed heart pumps, Shockwave lithotripsy devices, and contact lenses to hospitals and surgery centers, with much of the revenue coming from recurring disposables and implants.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of BlackRock, Inc. stack up against those of Johnson & Johnson.

BlackRock, Inc. competitive advantage: BlackRock's edge is scale combined with breadth. Running $15.3 trillion lets it price core iShares funds at 0.03% and still post a 44.1% adjusted operating margin in 2025, which smaller rivals cannot match. iShares also offers deep trading liquidity in many ETF categories, which matters to institutions moving large blocks. Aladdin adds a second moat: banks, insurers and pension funds that run their portfolios on it face high switching costs. Since 2024 BlackRock has added infrastructure (GIP), private credit (HPS) and private markets data (Preqin), so it can sell public and private assets plus the tools to monitor them in one relationship.

Johnson & Johnson competitive advantage: J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time. That diversification lets it absorb clinical-trial failures and patent expirations that would sink a single-product biotech, and fund multibillion-dollar acquisitions such as Abiomed, Shockwave Medical, and Intra-Cellular Therapies with cash and investment-grade debt.

Future prospects matter as much as current results. The growth strategies below explain how BlackRock, Inc. and Johnson & Johnson each plan to expand from here.

BlackRock, Inc. growth strategy: Growth now comes from four places. Private markets: GIP (closed October 2024, about $12.5 billion), HPS Investment Partners (closed July 2025, about $12 billion in stock) and ElmTree (2025) made BlackRock a major infrastructure and private credit manager, and GIP helped lead the $40 billion Aligned Data Centers purchase that closed in July 2026. Technology: Aladdin, eFront and Preqin data, with technology revenue up 13% year over year in Q2 2026. ETFs: iShares took in $310 billion of net inflows in the first half of 2026, and iShares Europe reached $1.5 trillion. Wealth and retirement: Aperio custom indexing (close to $200 billion), LifePath Paycheck ($30 billion) and digital asset products such as the iShares Bitcoin Trust.

Johnson & Johnson growth strategy: J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025). Internally it is expanding TREMFYA and CAPLYTA labels, advancing multiple myeloma combinations such as TALVEY plus DARZALEX FASPRO, and developing the OTTAVA soft-tissue surgical robot to compete with Intuitive Surgical's da Vinci.

A closer look at the financial trajectory of BlackRock, Inc. and Johnson & Johnson rounds out the comparison.

BlackRock, Inc.: BlackRock's revenue grew from $19.37 billion in 2021 to $24.22 billion in 2025, with a dip in 2022 and 2023 when stock and bond prices fell. Revenue jumped 19% in 2025 on higher markets, 9% organic base fee growth and fees from GIP and HPS. GAAP operating income fell 7% to $7.05 billion because of non-cash acquisition expenses and a charitable gift of Circle shares, but adjusted operating income rose 18% to $9.6 billion, a 44.1% margin. The firm returned $5 billion to shareholders in 2025 and raised its quarterly dividend 10% to $5.73 for 2026. In Q2 2026 revenue rose 31% to $7.08 billion, GAAP diluted EPS was $12.19 ($13.91 as adjusted), and planned buybacks were lifted to $550 million a quarter.

Johnson & Johnson: J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.